Johannes Schetelig, MD, discusses challenges with assessing haploidentical related vs mismatched unrelated donor transplantation in high-risk AML/ALL/MDS
Johannes Schetelig, MD, MSc
Advertisement
Johannes Schetelig, MD, MSc, is director of medical research at Deutsche Knochenmarkspenderdatei; as well as a professor at Technical University Dresden
Articles by Johannes Schetelig, MD, MSc
Johannes Schetelig, MD, discusses outcomes with haploidentical related vs mismatched unrelated donor transplantation in high-risk AML, ALL, and MDS.
Johannes Schetelig, MD, MSc, discusses whether patients with active relapsed/refractory acute myeloid leukemia (AML) should receive remission induction chemotherapy prior to undergoing allogenic hematopoietic stem cell transplant (allo-HCT).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5